rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BNP Predicts Heart Size, Function, and Death Risk in Kidney Failure Patients on Dialysis

RPEP-006552001Cataliotti, A; Malatino, L S; Jougasaki, M; Zoccali, C; Castellino, P; Giacone, G; Bellanuova, I; Tripepi, R; Seminara, G; Parlongo, S; Stancanelli, B; Bonanno, G; Fatuzzo, P; Rapisarda, F; Belluardo, P; Signorelli, S S; Heublein, D M; Lainchbury, J G; Leskinen, H K; Bailey, K R; Redfield, M M; Burnett, J C
Cross SectionalModerate evidence
The takeaway

In 112 dialysis patients, BNP was the strongest predictor of left ventricular hypertrophy and cardiac mortality, outperforming ANP and identifying the highest-risk patients for cardiovascular death.

Strongest death predictor

BNP outperformed all other natriuretic peptides for predicting cardiac mortality in 112 dialysis patients

What the researchers found

BNP was the strongest predictor of left ventricular hypertrophy and cardiac mortality in 112 ESRD dialysis patients, outperforming ANP for cardiovascular risk stratification in this high-risk population.

Why it matters

Dialysis patients have a 10-30x higher cardiovascular mortality than the general population. A simple blood test that identifies the highest-risk patients enables targeted preventive interventions.

How the study worked

Cross-sectional cohort study in 112 dialysis patients. Plasma BNP, ANP, and N-terminal ANP measured. Echocardiography assessed LVH. Cardiac mortality tracked during follow-up.

What this study cannot tell us

Cross-sectional study with follow-up. Dialysis timing relative to blood sampling can affect peptide levels. Specific BNP cutoff values for this population may differ from general cardiac patients.

How to read the evidence

Moderate evidence from a well-characterized cohort of 112 dialysis patients with echocardiographic correlation and mortality follow-up.

When this study was published

Published in 2001. BNP and NT-proBNP are now used in clinical nephrology for cardiovascular risk assessment in dialysis patients.

The bigger picture

Cardiovascular disease causes over 50% of dialysis patient deaths. BNP-guided risk stratification could enable aggressive cardiovascular prevention in the highest-risk subset of an already high-risk population.

Questions still open

  • Should BNP be measured routinely in all dialysis patients?
  • Can BNP-guided intervention reduce cardiac mortality in ESRD?
  • How should BNP be interpreted differently in dialysis vs non-dialysis patients?

Common questions

Why do dialysis patients have heart problems?
Kidney failure causes fluid overload, high blood pressure, and metabolic changes that strain the heart. Over 50% of dialysis patient deaths are from cardiovascular causes, making heart monitoring critical.
How does BNP help?
A simple blood test measuring BNP identifies which dialysis patients have the most enlarged, stressed hearts and the highest risk of cardiac death. This allows doctors to intensify treatment for the highest-risk patients.

Read the original research

Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.

Mayo Clinic proceedings, 76(11), 1111-9

View on PubMed ↗

Citation

Cataliotti, A; Malatino, L S; Jougasaki, M; Zoccali, C; Castellino, P; Giacone, G; Bellanuova, I; Tripepi, R; Seminara, G; Parlongo, S; Stancanelli, B; Bonanno, G; Fatuzzo, P; Rapisarda, F; Belluardo, P; Signorelli, S S; Heublein, D M; Lainchbury, J G; Leskinen, H K; Bailey, K R; Redfield, M M; Burnett, J C. (2001). Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.. Mayo Clinic proceedings, 76(11), 1111-9.